The Compounding Loophole

Short Q&A follow-up explaining the 'compounding loophole' for GLP-1 drugs: compounding pharmacies may make a drug during an FDA shortage, and semaglutide is in constant shortage, so telemedicine startups deliver it at ~$250-300/mo vs $1300 official. Covers how they source it (the same factories selling extra), why not cheaper (mystery; unit cost ~$5/mo), the safety FUD (the adverse-event-report comparison; the salt-vs-free-base non-issue, with the 'based' etymology), the upside (shortages are mostly regulatory - 'Adderall users, take note'), the modest hit to Novo Nordisk, and the looming dilemma when the shortage officially ends.

Quality 64 · Strong. Solid/Strong edge - a clear, useful, well-framed explainer of a real phenomenon with a genuine takeaway (the loophole as a natural experiment proving drug shortages are regulatory), but brief, topical, and Q&A-format rather than a developed argument.

Claude’s paradigm shift 35 · Slight. Slight-to-Moderate - the 'shortages are regulatory' point is a recurring Scott/libertarian theme, not novel here; the post documents a specific loophole.

Real-world impact 2 · Minor. Within-discourse health-policy explainer; the loophole itself helps many people get cheap drugs, but the post reports rather than causes it.